Company News
2025-12-06
Parent company Rhegen Biotech's lyophilized mRNA vaccine for herpes zoster (RH110) has initiated Phase II clinical trials.
#Rhegen Biotech's Lyophilized mRNA Vaccine for Herpes Zoster (RH110) Initiates Phase II Clinical Trials# Recently, the lyophilized mRNA vaccine for herpes zoster, RH110, independently developed by Rh...
Details
2025-12-06
Parent company Rhegen Biotech's lyophilized mRNA vaccine for tuberculosis (RH119) has received CDE approval for clinical trial application.
Details
2025-12-06
Parent Company Rhegen Biotech's Personalized mRNA Cancer Vaccine Clinical Study Initiated
Details